Tilray Brands (TLRY) Non Operating Income (2017 - 2026)
Tilray Brands (TLRY) posted Non Operating Income of $8.1 million for Q1 2026, up 165.74% on a QoQ basis from -$12.3 million in Q4 2025, and up 196.59% year-over-year from $2.7 million in Q1 2025.
Tilray Brands (TLRY) Non Operating Income (2017 - 2026) Analysis & Trends
Tilray Brands' Non Operating Income history runs 10 years deep, the most recent figure standing at $8.1 million for Q1 2026.
- Quarterly Non Operating Income rose 196.59% year-over-year to $8.1 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $3.8 million (up 118.35% YoY) and the FY2025 annual result came in at -$30.0 million, up 20.85% from the prior year.
- Non Operating Income was $8.1 million for Q1 2026 at Tilray Brands, up from -$12.3 million in the prior quarter.
- Across five years, Non Operating Income topped out at $220.1 million in Q2 2022 and bottomed at -$17.2 million in Q1 2024.
- A 5-year average of $12.3 million and a median of -$3.1 million in 2022 frame the typical range for Non Operating Income.
- Peak annual rise in Non Operating Income reached 387.28% in 2024, while the deepest fall reached 1557.6% in 2024.
- Tilray Brands' Non Operating Income stood at -$3.1 million in 2022, then soared by 126.42% to $821000.0 in 2023, then sank by 1045.92% to -$7.8 million in 2024, then tumbled by 58.51% to -$12.3 million in 2025, then surged by 165.74% to $8.1 million in 2026.
- Business Quant data shows TLRY's Non Operating Income at $8.1 million in Q1 2026, -$12.3 million in Q4 2025, and -$6.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -216.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 20.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -7.50 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 53.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Tilray Brands | 465.02 Mn | 373.06 Mn | 54.95 Mn | 8.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 8.09 Mn |
| Nov 30, 2025 | -12.31 Mn |
| Aug 31, 2025 | -6.70 Mn |
| May 31, 2025 | 14.68 Mn |
| Feb 28, 2025 | -8.38 Mn |
| Nov 30, 2024 | -7.77 Mn |
| Aug 31, 2024 | 12.65 Mn |
| May 31, 2024 | -17.02 Mn |
| Feb 29, 2024 | -17.24 Mn |
| Nov 30, 2023 | 821,000.00 |
| Aug 31, 2023 | -4.40 Mn |
| May 31, 2023 | 36.64 Mn |
| Feb 28, 2023 | -1.04 Mn |
| Nov 30, 2022 | -3.11 Mn |
| Aug 31, 2022 | -4.41 Mn |
| May 31, 2022 | 220.09 Mn |
| Feb 28, 2022 | -2.31 Mn |
| Nov 30, 2021 | -9.94 Mn |
| Aug 31, 2021 | 49.70 Mn |
| May 31, 2021 | 121.51 Mn |